• Innovent Biologics entered a global licensing and collaboration deal with Pfizer to develop 12 early-stage oncology programs spanning ADCs, multi-specific antibodies.
• Innovent runs development through Phase 1; Pfizer then leads global development, with a mix of co-development and exclusive licensing structures.
• Deal terms include USD 650 million upfront, up to USD 9.85 billion in milestones, up to double-digit royalties; profit-share in the U.S. and Europe for select programs.
• Transaction closing remains subject to required regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260529-12175852), on May 28, 2026, and is solely responsible for the information contained therein.